https://scholars.lib.ntu.edu.tw/handle/123456789/627195
標題: | Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma | 作者: | Rimassa, Lorenza Kelley, Robin Kate Meyer, Tim Ryoo, Baek-Yeol Merle, Philippe Park, Joong-Won Blanc, Jean-Frederic Lim, Ho Yeong Tran, Albert Chan, Yi-Wah McAdam, Paul Wang, Evelyn ANN-LII CHENG El-Khoueiry, Anthony B Abou-Alfa, Ghassan K |
關鍵字: | Cabozantinib; Hepatocellular carcinoma; Plasma biomarkers; Prognostic factors | 公開日期: | 一月-2022 | 出版社: | KARGER | 卷: | 11 | 期: | 1 | 來源出版物: | Liver cancer | 摘要: | Cabozantinib, an inhibitor of MET, AXL, and VEGF receptors, significantly improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with previously treated advanced hepatocellular carcinoma (HCC). In this exploratory analysis, outcomes were evaluated according to plasma biomarker levels. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/627195 | ISSN: | 2235-1795 | DOI: | 10.1159/000519867 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。